Loading...
Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management
The introduction of immunotherapy to treat recurrent/metastatic head and neck squamous cell carcinoma in 2016 has provided new valuable treatment options to many cancer patients. Pembrolizumab and nivolumab, which are classified as immune checkpoint inhibitors of programmed cell death protein 1, hav...
Saved in:
| Published in: | J Adv Pract Oncol |
|---|---|
| Main Author: | |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Harborside Press LLC
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7522658/ https://ncbi.nlm.nih.gov/pubmed/33014516 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2019.10.2.12 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|